Black Rock Inc. Connect Biopharma Holdings LTD Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Connect Biopharma Holdings LTD stock. As of the latest transaction made, Black Rock Inc. holds 103,891 shares of CNTB stock, worth $84,151. This represents 0.0% of its overall portfolio holdings.

Number of Shares

103,891

Previous 1,040,067 90.01%

Holding current value

$84,151

Previous $1.81 Million 91.32%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 13, 2024	SELL	$1.28 - $2.2 $1.2 Million - $2.06 Million	-936,176 Reduced 90.01%	103,891 $157,000
Q4 2023 Feb 13, 2024	SELL	$0.7 - $2.06 $59,636 - $175,501	-85,195 Reduced 7.57%	1,040,067 $1.23 Million
Q4 2022 Feb 13, 2023	SELL	$0.64 - $1.31 $192,746 - $394,527	-301,166 Reduced 21.11%	1,125,262 $978,000
Q3 2022 Nov 14, 2022	SELL	$0.8 - $1.65 $6,825 - $14,077	-8,532 Reduced 0.59%	1,426,428 $1.84 Million
Q2 2022 Aug 12, 2022	SELL	$0.56 - $3.25 $448,801 - $2.6 Million	-801,432 Reduced 35.84%	1,434,960 $1.25 Million
Q1 2022 May 12, 2022	BUY	$2.46 - $5.92 $227,874 - $548,381	92,632 Added 4.32%	2,236,392 $6.76 Million
Q4 2021 Feb 10, 2022	SELL	$4.26 - $23.33 $1.3 Million - $7.15 Million	-306,305 Reduced 12.5%	2,143,760 $11 Million
Q3 2021 Nov 09, 2021	SELL	$18.12 - $28.5 $146,174 - $229,909	-8,067 Reduced 0.33%	2,450,065 $59.4 Million
Q2 2021 Aug 11, 2021	BUY	$14.16 - $19.53 $34.8 Million - $48 Million	2,458,132 New	2,458,132 $48 Million

Others Institutions Holding CNTB

# of Institutions

Shares Held

3.28M

Call Options Held

14K

Put Options Held

View Full List

About Connect Biopharma Holdings Ltd

Ticker CNTB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,015,800
Market Cap $44.6M
Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for t...

More about CNTB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account